Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Annie Daly is a freelance writer and editor covering all things wellness, travel, and culture. Prior to going freelance, she was a digital editor at SELF, BuzzFeed Travel, and Yahoo! Travel, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback